Literature DB >> 21498151

Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.

Susan Swindells1, Hongyu Jiang, A Lisa Mukherjee, Mark Winters, Ronald J Bosch, David Katzenstein.   

Abstract

BACKGROUND: We hypothesized that drug resistance mutations would impact clinical outcomes associated with HIV-1 infection.
METHODS: A matched case-control study of participants in AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT). Cases experienced an AIDS-defining event (ADE) or mortality, and controls did not. One hundred thirty-four cases were identified and matched to a total of 266 controls by age, sex, treatment regimen, and length of follow-up. Both cases and controls had HIV RNA levels of ≥ 500 copies/mL within 24 weeks of an event. Population-based genotyping at or near the time of the event was used to evaluate the impact of resistance mutations on incidence of ADE and/or death using conditional logistic regression models.
RESULTS: One hundred four cases and 183 controls were analyzed. Median time to event was 99 weeks; 6 cases were deaths. At baseline, cases had lower CD4 (median 117 vs 235 cells/mm3; P < .0001) and higher HIV RNA levels (median 205,000 vs 57,000 copies/mL; P = .003). No significant differences in resistance were seen between cases and controls.
CONCLUSIONS: In this rigorously designed case-control study, lower CD4 cell counts and higher virus loads, not antiretroviral drug resistance, were strongly associated with ADE and mortality.

Entities:  

Mesh:

Year:  2011        PMID: 21498151      PMCID: PMC3320087          DOI: 10.1310/hct1202-79

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  33 in total

1.  A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

Authors:  Scott M Hammer; Roland Bassett; Kathleen E Squires; Margaret A Fischl; Lisa M Demeter; Judith S Currier; John W Mellors; Gene D Morse; Joseph J Eron; Jorge L Santana; Victor DeGruttola
Journal:  Antivir Ther       Date:  2003-12

2.  A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

Authors:  Margaret A Fischl; Heather J Ribaudo; Ann C Collier; Alejo Erice; Marina Giuliano; Marjorie Dehlinger; Joseph J Eron; Michael S Saag; Scott M Hammer; Stefano Vella; Gene D Morse; Judith E Feinberg; Lisa M Demeter; Susan H Eshleman
Journal:  J Infect Dis       Date:  2003-08-15       Impact factor: 5.226

3.  Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

Authors:  R L Murphy; R M Gulick; V DeGruttola; R T D'Aquila; J J Eron; J P Sommadossi; J S Currier; L Smeaton; I Frank; A M Caliendo; J G Gerber; R Tung; D R Kuritzkes
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

4.  Assessing resistance costs of antiretroviral therapies via measures of future drug options.

Authors:  Hongyu Jiang; Steven G Deeks; Daniel R Kuritzkes; Marc Lallemant; David Katzenstein; Mary Albrecht; Victor DeGruttola
Journal:  J Infect Dis       Date:  2003-09-23       Impact factor: 5.226

5.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

6.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

7.  Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Authors:  Scott M Hammer; Florin Vaida; Kara K Bennett; Mary K Holohan; Lewis Sheiner; Joseph J Eron; Lawrence Joseph Wheat; Ronald T Mitsuyasu; Roy M Gulick; Fred T Valentine; Judith A Aberg; Michael D Rogers; Cheryl N Karol; Alfred J Saah; Ronald H Lewis; Laura J Bessen; Carol Brosgart; Victor DeGruttola; John W Mellors
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

8.  Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing.

Authors:  Gregory M Lucas; Joel E Gallant; Richard D Moore
Journal:  AIDS       Date:  2004-07-23       Impact factor: 4.177

9.  Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.

Authors:  Magdalena A Recsky; Zabrina L Brumme; Keith J Chan; Brian Wynhoven; Benita Yip; Winnie W Y Dong; Katherine V Heath; Julio S G Montaner; Adrian R Levy; Robert S Hogg; P Richard Harrigan
Journal:  J Infect Dis       Date:  2004-06-11       Impact factor: 5.226

10.  Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Authors:  Muriel Vray; Jean-Luc Meynard; Cécile Dalban; Laurence Morand-Joubert; François Clavel; Françoise Brun-Vézinet; Gilles Peytavin; Dominique Costagliola; Pierre-Marie Girard
Journal:  Antivir Ther       Date:  2003-10
View more
  2 in total

1.  Social support as a predictor of early diagnosis, linkage, retention, and adherence to HIV care: results from the steps study.

Authors:  J Daniel Kelly; Christine Hartman; James Graham; Michael A Kallen; Thomas P Giordano
Journal:  J Assoc Nurses AIDS Care       Date:  2014-02-06       Impact factor: 1.354

2.  Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.

Authors:  Kate Buchacz; Bryan Lau; Yuezhou Jing; Ronald Bosch; Alison G Abraham; M John Gill; Michael J Silverberg; James J Goedert; Timothy R Sterling; Keri N Althoff; Jeffrey N Martin; Greer Burkholder; Neel Gandhi; Hasina Samji; Pragna Patel; Anita Rachlis; Jennifer E Thorne; Sonia Napravnik; Keith Henry; Angel Mayor; Kelly Gebo; Stephen J Gange; Richard D Moore; John T Brooks
Journal:  J Infect Dis       Date:  2016-04-18       Impact factor: 5.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.